Top Markets
Coin of the day
Synairgen plc Synairgen plc

Synairgen plc

SNG
주식 순위 #40400
Synairgen plc specializes in the research and development of pharmaceutical... Synairgen plc specializes in the research and development of pharmaceutical treatments for various respiratory conditions. Its product pipeline includes SNG001, an inhaled interferon beta currently being developed for COVID-19. The company is also advancing an inhaled form of interferon beta (IFN-ß) through Phase II clinical trials for the management of asthma triggered by common colds and influenza, as well as for the treatment or prevention of chronic obstructive pulmonary disease. Furthermore, Synairgen is developing a LOXL2 inhibitor intended for treating idiopathic pulmonary fibrosis (IPF). To support the development of this LOXL2 inhibitor, the company maintains a licensing and collaboration agreement with Pharmaxis Ltd. Synairgen plc was established in 2004 and is headquartered in Southampton, United Kingdom.
주가
$0.01292666
마지막 동기화: 2025-04-08
시가총액
$157.54K
변동 (1일)
6.84%
변동 (1년)
0.00%
국가
GB
거래 Synairgen plc (SNG)

카테고리

Synairgen plc (SNG)의 EPS
June 2024 기준 EPS TTM: $-0.04
Synairgen plc의 최신 재무 보고서와 주가에 따르면, 현재 EPS (TTM)는 $-0.04입니다. 2022년 말에는 회사의 EPS가 $-0.11였으며, 이는 2021년의 EPS $-0.32와 감소입니다.
Synairgen plc의 EPS 기록 (2004 ~ 2026)
매년 말의 EPS
연도 EPS 변화
2026 (TTM) $-0.04 -13.00%
2023 $-0.05 -49.81%
2022 $-0.11 -67.33%
2021 $-0.32 150.97%
2020 $-0.13 176.28%
2019 $-0.05 5.88%
2018 $-0.04 -274.70%
2017 $0.03 -166.75%
2016 $-0.04 4.12%
2015 $-0.04 -273.33%
2014 $0.02 -146.98%
2013 $-0.04 -11.13%
2012 $-0.05 -41.31%
2011 $-0.09 34.96%
2010 $-0.06 -65.03%
2009 $-0.18 -7.49%
2008 $-0.20 44.55%
2007 $-0.14 67.04%
2006 $-0.08 39.93%
2005 $-0.06 112.04%
2004 $-0.03 0.00%
유사 기업 또는 경쟁사의 EPS
회사 EPS EPS 차이 국가
$17.32 -39,916.09%
US
$27.74 -63,870.11%
NL
- -
CH
- -
KR
$13.70 -31,594.48%
BE